AstraZeneca And Daiichi Eyeing Tumor-Agnostic Future For Enhertu?
Pan-Tumor Approach Pays Off So Far
The ability of Daiichi-Sankyo/AstraZeneca’s blockbuster antibody-drug conjugate Enhertu to tackle a range of HER2-expressing cancers in a Phase II study could lead to a tumor-agnostic future for the product, new data suggest.
